title: The role of statins in the setting of HIV infection.
abstract: HIV-infected individuals are at an increased risk of cardiovascular disease (CVD) and other HIV-related co-morbidities. This is due in part to dyslipidemia associated with antiretroviral therapy and increased inflammation and immune activation from chronic HIV infection. Statins not only have potent lipid-lowering properties but are also anti-inflammatory and immunomodulators. Studies suggest that statin therapy in the HIV-infected population may decrease the risk of CVD and other non-AIDS-defining co-morbidities. This review summarizes the recent literature on statin use in the HIV setting.
authors.affiliation: Departments of Pediatrics and Medicine, Divisions of Infectious Diseases, Medical University of South Carolina, 135 Rutledge Ave, MSC 752, Charleston, SC, 29425, USA, eckarda@musc.edu.
authors.forename: Allison Ross
authors.initials: AR
authors.lastname: Eckard
authors.forename: Grace A
authors.initials: GA
authors.lastname: McComsey
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects; D044966:Anti-Retroviral Agents / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D050171:Dyslipidemias / Q000188:drug therapy* / Q000209:etiology; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D012307:Risk Factors
chemical_list: D019380:Anti-HIV Agents; D044966:Anti-Retroviral Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors